Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice

[1]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[2]  F. Cardoso,et al.  Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial) , 2016 .

[3]  V. Torri,et al.  PO64 METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2- ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY , 2015 .

[4]  M. Colleoni,et al.  Clinical overview of metronomic chemotherapy in breast cancer , 2015, Nature Reviews Clinical Oncology.

[5]  A. Palazzo,et al.  1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination , 2015 .

[6]  N. Rahman,et al.  Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012) , 2015 .

[7]  A. González-Neira,et al.  Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. , 2015, The oncologist.

[8]  E. Perez,et al.  Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Scarpa,et al.  On and off Metronomic Oral Vinorelbine in Elderly Women with Advanced Breast Cancer , 2015, Tumori.

[10]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[11]  D. Doval,et al.  Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[12]  G. Hortobagyi,et al.  Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Puglisi,et al.  Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[14]  M. Gnant,et al.  Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer , 2014, Breast Care.

[15]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Colleoni,et al.  Metronomic therapy and breast cancer: a systematic review. , 2014, Cancer treatment reviews.

[17]  E. Espinosa,et al.  403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Perez,et al.  361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  N. André,et al.  Metronomics: towards personalized chemotherapy? , 2014, Nature Reviews Clinical Oncology.

[20]  E. Winer,et al.  Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. André,et al.  Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch , 2014, Front. Oncol..

[22]  V. Torri,et al.  Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study , 2014, International journal of breast cancer.

[23]  E. Winer,et al.  Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  Eld,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.

[25]  Marisa C. Jenkins,et al.  Combination versus sequential single agent chemotherapy for metastatic breast cancer. , 2013, The Cochrane database of systematic reviews.

[26]  R. Kerbel,et al.  Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. , 2013, Breast.

[27]  M. Campone,et al.  A Three‐Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines , 2013, The breast journal.

[28]  Y. Rostom,et al.  All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer , 2013, Cancer Chemotherapy and Pharmacology.

[29]  S. Verma,et al.  Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[30]  M. Caraglia,et al.  Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases , 2012, Cancer Chemotherapy and Pharmacology.

[31]  J. Sakamoto,et al.  Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer , 2012, Cancer Chemotherapy and Pharmacology.

[32]  M. Aapro,et al.  Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. , 2012, Cancer Treatment Reviews.

[33]  N. Robert,et al.  Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. , 2012, The oncologist.

[34]  M. Valerio,et al.  Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. , 2012, Anticancer research.

[35]  M. Dickler,et al.  RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2012 .

[36]  D. Tripathy,et al.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer , 2012 .

[37]  A. Nacci,et al.  Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. , 2012, European journal of cancer.

[38]  Jin-song Lu,et al.  An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study , 2012, Cancer Chemotherapy and Pharmacology.

[39]  Linda J. M. Oostendorp,et al.  Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. , 2011, The Lancet. Oncology.

[40]  P. Zahedi,et al.  Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer , 2011, Molecular Cancer Therapeutics.

[41]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Agelaki,et al.  Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. , 2011, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[43]  A. Negassa,et al.  Phase I trial of metronomic oral vinorelbine in patients with advanced cancer , 2011, Cancer Chemotherapy and Pharmacology.

[44]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Thigpen.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011 .

[46]  R. Kerbel,et al.  Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. , 2011, Neoplasia.

[47]  G. Klement,et al.  Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? , 2011, Journal of pediatric hematology/oncology.

[48]  C. Doreau,et al.  Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. , 2011, Journal of oncology practice.

[49]  A. Schneeweiss,et al.  Acceptance of oral chemotherapy in breast cancer patients - a survey study , 2011, BMC Cancer.

[50]  A. Schneeweiss,et al.  First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. , 2010, European journal of cancer.

[51]  G. Botti,et al.  Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. , 2010, Clinical breast cancer.

[52]  Bing-he Xu,et al.  Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Llombart-Cussac,et al.  Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC). , 2010 .

[54]  H. Sommer,et al.  Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes , 2010, Cancer Chemotherapy and Pharmacology.

[55]  U. Dafni,et al.  Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer , 2009, Clinical Cancer Research.

[56]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy , 2009, Journal of the National Cancer Institute.

[57]  M. Espié,et al.  All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial , 2009, British Journal of Cancer.

[58]  R. Shoemaker,et al.  Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition , 2009, Molecular Cancer Therapeutics.

[59]  S. Filip,et al.  A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. , 2009, Anticancer research.

[60]  J. Thigpen.  Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study , 2009 .

[61]  Ann Partridge,et al.  Patient adherence and persistence with oral anticancer treatment , 2009, CA: a cancer journal for clinicians.

[62]  A. Goldhirsch,et al.  Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer , 2009, Cancer Chemotherapy and Pharmacology.

[63]  A. Goldhirsch,et al.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Martín,et al.  Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer , 2008, Journal of chemotherapy.

[65]  A. Wardley,et al.  Effective oral chemotherapy for breast cancer: pillars of strength. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[67]  M. Espié,et al.  2130 POSTER Updated analysis of an international phase II study evaluating an all-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer (MBC) , 2007 .

[68]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[69]  Christophe Tournigand,et al.  Impact of chemotherapy beyond the first line in patients with metastatic breast cancer , 2007, Breast Cancer Research and Treatment.

[70]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[71]  A. Goldhirsch,et al.  Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer , 2006, BMC Cancer.

[72]  A. Goldhirsch,et al.  Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer , 2006, Anti-cancer drugs.

[73]  A. Goldhirsch,et al.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. , 2006, Blood.

[74]  M. Guida,et al.  Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  A. Goldhirsch,et al.  Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  P. Conte,et al.  Oral vinorelbine in metastatic breast cancer , 2005, Breast Cancer Research.

[77]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Stockler,et al.  Duration of chemotherapy for metastatic breast cancer , 2004 .

[79]  R. Kerbel,et al.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A. Schindler,et al.  Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[82]  T. Delozier,et al.  Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  H. Burger,et al.  Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines , 2002, British Journal of Cancer.

[84]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.

[85]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  M. Munsell,et al.  Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy , 2002, Bone Marrow Transplantation.

[87]  A. Buzdar,et al.  Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.

[88]  H. Burger,et al.  Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  D. Amadori,et al.  Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC) , 2001 .

[90]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  P. Zola,et al.  Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. , 1997, Anticancer research.

[92]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.